Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Luciano Costa waited three years to see how patients with an aggressive bone-marrow cancer would fare on an experimental immunotherapy treatment. Reviewing the results gave him goose bumps. “Holy shit ...

Stage 3 multiple myeloma is defined by high beta-2 microglobulin, elevated LDH, and high-risk genetic abnormalities. Diagnosis involves CRAB criteria and tests like bone marrow biopsy, imaging, and ...

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure. This large immune cell ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Rochester biotech company ...

This panel of multiple myeloma care partners shares diverse diagnostic journeys, offering vital insights for patients and caregivers. This panel of multiple myeloma care partners shares diverse ...

ROCHESTER, Minn. — A recent study by Mayo Clinic published in the New England Journal of Medicine has revealed promising results for treating extramedullary multiple myeloma using a dual-antibody ...

ROCHESTER, Minn. — A new Mayo Clinic study published in the New England Journal of Medicine has uncovered that an off-the-shelf, dual-antibody therapy can generate deep and durable responses in ...

In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with ...